摘要
目的:观察普拉克索联合左旋多巴治疗帕金森病(PD)患者的效果。方法:选取2020年1月至2021年6月该院收治的90例PD患者进行前瞻性研究,按照随机数字表法分为对照组和观察组各45例。对照组采用左旋多巴治疗,观察组在对照组基础上联合普拉克索治疗,比较两组治疗前后运动功能[UPDRS 3.0版运动检查法(UPDRSⅢ)]评分,平衡能力[Berg平衡量表(BBS)]评分,miR-124和miR-137水平,精神状态[汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)评分,认知功能[蒙特利尔认知评估量表(MoCA)]评分,生活质量[帕金森生活质量问卷(PDQ-39)]评分及不良反应发生率。结果:治疗后,观察组UPDRSⅢ评分低于对照组,BBS评分高于对照组,差异均有统计学意义(P<0.05);观察组miR-124水平高于对照组,miR-137水平低于对照组,差异均有统计学意义(P<0.05);观察组HAMA、HAMD、PDQ-39评分均低于对照组,MoCA评分高于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:普拉克索联合左旋多巴治疗PD患者,可提高患者运动功能和平衡能力,调节miR-124、miR-137表达,改善精神状态、认知功能和生活质量,其效果优于单纯左旋多巴治疗。
Objective:To observe effects of Pramipexole combined with Levodopa in treatment of patients with Parkinson’s disease(PD).Methods:A prospective study was conducted on 90 PD patients admitted to the hospital from January 2020 to June 2021.They were divided into control group and observation group according to the random number table method,45 cases in each.The control group was treated with Levodopa,while the observation group was treated with Pramipexole on the basis of that of the control group.The motor function[UPDRS version 3.0 motor examination(UPDRS Ⅲ)]score,the balance ability[Berg balance scale(BBS)]score,the miR-124 and miR-137 levels,the mental state[Hamilton anxiety scale(HAMA),Hamilton depression scale(HAMD)]scores,the cognitive function[Montreal cognitive assessment(MoCA)]score,the quality of life[Parkinson’s quality of life questionnaire(PDQ-39)]score,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the UPDRS Ⅲ score of the observation group was lower than that of the control group,the BBS score was higher than that of the control group,and the differences were statistically significant(P<0.05).The level of miR-124 in the observation group was higher than that in the control group,the level of miR-137 was lower than that in the control group,and the differences were statistically significant(P<0.05).The HAMA,HAMD and PDQ-39 scores of the observation group were lower than those of the control group,the MoCA score was higher than that of the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Pramipexole combined with Levodopa in the treatment of the PD patients can improve the motor function and the balance ability,regulate the expressions of miR-124 and miR-137,and improve the mental state,the cognitive function and the quality of life.Moreover,it is superior to si
作者
赵津璋
ZHAO Jinzhang(1^(st) Department of Neurology of the Central Hospital of Jiamusi City,Jiamusi 154002 Heilongjiang,China)
出处
《中国民康医学》
2022年第20期36-38,48,共4页
Medical Journal of Chinese People’s Health
关键词
帕金森病
普拉克索
左旋多巴
运动功能
认知功能
平衡能力
Parkinson’s disease
Pramipexole
Levodopa
Motor function
Cognitive function
Balance ability